BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Probing single-cell biology ex vivo for personalized systems medic
 ine
DTSTART:20230418T110000
DTEND:20230418T120000
DTSTAMP:20260427T220732Z
UID:2ef30b3955bffe9d88c7ffb87dddd9e83ba9abeabe58afda61e84e2b
CATEGORIES:Conferences - Seminars
DESCRIPTION:Berend Snijder \nAssistant Professor of Molecular Systems Biol
 ogy at the ETH Zurich\nAbstract: \n\nThe cellular and molecular systems t
 hat determine drug responses in cancer are complex\, highly individual\, a
 nd incompletely understood. As a result\, identifying effective treatments
  for individual patients is still often challenging\, particularly in rela
 psed disease. To tackle this challenge\, we are developing Pharmacoscopy\,
  which allows the measurement of hundreds of ex vivo drug responses in s
 mall patient biopsies by immunofluorescence\, automated confocal microscop
 y\, single-cell image analysis\, and machine learning. In this talk\, I wi
 ll show: 1) Results from interventional clinical trials showing that Pharm
 acoscopy identifies effective treatments\; 2) How we can use deep learning
  and spatial analyses to discover new cancer and immune cell phenotypes\; 
 And 3) how\, when combined with patient-centric multi-OMIC measurements an
 d matched patient data\, Pharmacoscopy enables the identification of the m
 olecular and cellular systems that govern treatment response individuality
 .\n \n\n© 2023 EPFL\n\n\nBio:\nBerend Snijder is an Assistant Professor 
 of Molecular Systems Biology at the ETH Zurich in Switzerland\, as well as
  a group leader at the Swiss Institute of Bioinformatics and the Comprehen
 sive Cancer Center Zurich\, with funding support from the Swiss National S
 cience Foundation\, an ERC Starting Grant\, and public/private partnership
 s with pharmaceutical companies\, among others. Berend received his MSc de
 gree in Biomedical Sciences with honors from the University of Amsterdam a
 nd performed his Ph.D. studies working on image-based screening and cell-t
 o-cell variability analyses in the lab of Lucas Pelkmans at the IMSB\, ETH
  Zurich\, for which he was awarded the ETH Medal. For his postdoctoral stu
 dies\, he joined the lab of Giulio Superti-Furga at the Center for Molecul
 ar Medicine in Vienna\, where he received a Young Investigator Award from 
 the Austrian Society for Hematology and Medical Oncology\, and co-founded 
 the biotech Allcyte GmbH\, acquired in 2021. The Snijder lab is pioneering
  Pharmacoscopy\, a method to measure ex vivo drug responses in patient b
 iopsies using automated microscopy\, image analysis\, and deep learning to
  improve treatment selection in cancer and gain systems-level insights int
 o why patients respond differently to medications. Please see https://sni
 jderlab.org for more information.\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 https://epfl.zoom.u
 s/j/66192704532
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR